A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors

Abstract

Eighty-one first-time normal donors underwent leukapheresis for peripheral blood progenitor cell (PBPC) collection after mobilization with filgrastim administered either twice-daily (6 μg/kg every 12 h: n = 40) or once-daily (12 μg/kg: n = 41) subcutaneously for 3 d. The groups were similar for age, donor blood volume and target CD34+ cell dose to be collected (≤ 4 x 106 CD34+ cells/kg recipient). There was no statistically significant difference in the apheresis yield of CD34+ PBPCs (x 106) per kg recipient weight (5·6 ± 3·3 vs. 5·6 ± 4·3: P = 0·94) and per litre of blood processed (30± 17·2 vs. 30·4 ± 19·5: P = 0·92).